Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Novartis (NVS) reported $13.34 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 1.4%. EPS of $2.03 for the same period compares to $1.98 a year ago.The reported revenue represents a surprise of -2.67% over the Zacks Consensus Estimate of $13.7 billion. With the consensus EPS estimate being $1.99, the EPS surprise was +2.14%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Novartis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Immunology- Ilaris- US: $294 million versus the three-analyst average estimate of $284.6 million. The reported number represents a year-over-year change of +26.2%.Revenues- Immunology- Ilaris- ROW: $220 million versus the three-analyst average estimate of $212.16 million. The reported number represents a year-over-year change of +22.2%.Revenues- Established Brands- Exforge Group- ROW: $180 million versus the three-analyst average estimate of $160.03 million. The reported number represents a year-over-year change of +14.7%.Revenues- Established Brands- Diovan Group- US: $8 million compared to the $7.04 million average estimate based on three analysts. The reported number represents a change of +14.3% year over year.Revenues- Oncology- Tafinlar + Mekinist- Total: $540 million compared to the $538.87 million average estimate based on three analysts. The reported number represents a change of +2.5% year over year.Revenues- Net sales to third parties: $13.34 billion versus the three-analyst average estimate of $13.7 billion. The reported number represents a year-over-year change of +1.4%.Revenues- Oncology- Kisqali- Total: $1.32 billion versus $1.49 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +46.5% change.Revenues- Immunology- Cosentyx- Total: $1.81 billion versus $1.66 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.2% change.Revenues- Cardiovascular- Entresto- Total: $1.25 billion versus $1.54 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -42.5% change.Revenues- Established Brands- Galvus Group- Total: $114 million versus $126.48 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -20.8% change.Revenues- Established Brands- Exforge Group- Total: $181 million versus $162.86 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.8% change.Revenues- Established brands- Kymriah- Total: $85 million compared to the $95.24 million average estimate based on three analysts. The reported number represents a change of -21.3% year over year.View all Key Company Metrics for Novartis here>>>Shares of Novartis have returned +5.3% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Free Report: Profiting from the 2nd Wave of AI ExplosionThe next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.Investors who bought shares like Nvidia at the right time have had a shot at huge gains.But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks